In this episode, our host Chris LaVictoire Mahai catches up with long-time friend, Lee Jones, Founder, former President, and CEO of Rebiotix Inc., to explore another avenue in our podcast series around healthcare’s steady movement towards personalized medicine and care. Leveraging Lee’s extensive background in biotechnology, medical device, and work with medical professionals around the world, Chris and Lee explore the role of personalization in the way medications and therapies are developed and delivered across the diagnosis and treatment phase: from clinical trial input, to initiating and adapting standardized therapies, to streamlining patient care pathways.

New this season! Each episode features consumer voices and testimonials based on their experiences, allowing us to truly orient our conversations from the “outside-in.” Thank you to those who shared their experiences with us.

About our guest

Lee Jones is the Founder, former President, and Chief Executive Officer of Rebiotix Inc., a Ferring Company. Lee has over 35 years of experience as a medical technology executive and entrepreneur in large and small companies and academia. With Rebiotix, Lee is leading a fast-paced effort to develop a new way of treating disease through Microbiota Restoration Therapy (MRT) and currently serves as the Senior Advisor to Ferring for the development and advancement of the company’s microbiome platform. Lee has a long track record of successful innovations across the healthcare spectrum, Lee understands the challenges and value of bringing new ideas to life that can serve patients and health care professionals more effectively. 

Lee also serves on several public and private boards. She has a BS in Chemical Engineering from the University of Minnesota and an Executive Management degree from the Carlson School of Management at the University of Minnesota.

About Rebiotix Inc.

Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.

The company is on the forefront of an exciting potential medical breakthrough with their MRT™ drug platform.  The MRT drug platform is leveraged to develop formulations consisting of live microbes, which are evaluated through their clinical program for the ability to address challenging diseases.

Rebiotix looks to deliver on the promise of microbiome-based therapeutics, starting with the goal of restoring the gut microbiota via standardized and stabilized investigational drugs developed and tested under guidance of US and non-US regulatory authorities.

You can learn more about Rebiotix at their website: www.rebiotix.com.

Memorable quotes from this episode:

“In Minnesota, for example, we’ve seen a great decrease in the cost of caring for diabetes patients. […] Getting people to the right doctors, getting the right medications, the right dosage, early on, has saved enormous amounts of money on the back end.”

Lee Jones

“Right now wealthy people can afford to go to clinics and have a concierge. And that person basically ushers them through the clinic, to the right doctors, to the right tests, so that they don’t have to spend their time trying to figure it all out. […] In my imaginary perfect world, I would have concierges for everyone, because most people don’t have the time or the ability to read all this stuff. All the medications, understand it, try to distill it, bring it home to themselves and then advocate on their behalf. I think that’s asking a lot.“

Lee Jones